<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514514</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ADE13</org_study_id>
    <secondary_id>2006-007021-32</secondary_id>
    <nct_id>NCT00514514</nct_id>
  </id_info>
  <brief_title>Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen</brief_title>
  <official_title>Multi-center, Open-label, Prospective, Randomized, Parallel Group, Long-term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI-free Regimen and a CNI-low Dose Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare renal function of immunosuppressive regimens with
      different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low
      dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
    <description>Demonstrate superiority of CNI-Free vs Standard Regimen in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. P-values are not adjusted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR Via Nankivell Formula at Month 12 - All Regimens</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
    <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR at Month 12 Utilizing Modification of Diet in Renal Disease (MDRD) Method</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
    <description>Change in GFR (Modification of Diet in Renal Disease calculated using the -MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR at Month 12 Utilizing Cockcroft-Gault Formula</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
    <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Creatinine From Month 3 to Month 12</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
    <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Event Data From Baseline 2 (Month 3) to Month 6</measure>
    <time_frame>From Baseline 2 (Month 3) to Month 6</time_frame>
    <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Event Data Baseline 2 (Month 3) to Month 12</measure>
    <time_frame>From Baseline 2 (Month 3) to Month 12</time_frame>
    <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL2 (Month 3) to Month 12 in Cardiovascular Risk (Framingham Score; 10-year Cardiovascular Risk)</measure>
    <time_frame>From Baseline 2 (Month 3) to Month 12</time_frame>
    <description>The Framingham Score (based on LDL cholesterol level) estimates the coronary heart disease risk (%) of developing one of the following coronary heart diseases: angina pectoris, myocardial infarction, or coronary disease death, over the course of 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR Calculated Via Nankivell Formula at Month 60</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 60</time_frame>
    <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR at Month 60 Utilizing Cockcroft-Gault Formula</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
    <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl) For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR at Month 60 Utilizing Modification of Diet in Renal Disease (MDRD) Method</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
    <description>Change in GFR (Modification of Diet in Renal Disease calculated using the -MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Creatinine From Month 3 to Month 60</measure>
    <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
    <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Event Data After Month 12 to Month 60</measure>
    <time_frame>Events starting after Month 12</time_frame>
    <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">802</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>CNI standard regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNI free regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNI low regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen</description>
    <arm_group_label>CNI free regimen</arm_group_label>
    <arm_group_label>CNI low regimen</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>1 tablet containing 180 mg or 360 mg
Dosing schedule:
Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)</description>
    <arm_group_label>CNI standard regimen</arm_group_label>
    <arm_group_label>CNI free regimen</arm_group_label>
    <other_name>Enteric Coated Mycophenolate Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandimmun Optoral</intervention_name>
    <description>1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level</description>
    <arm_group_label>CNI standard regimen</arm_group_label>
    <arm_group_label>CNI free regimen</arm_group_label>
    <arm_group_label>CNI low regimen</arm_group_label>
    <other_name>Cyclosporine A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simulect®</intervention_name>
    <description>Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4</description>
    <arm_group_label>CNI standard regimen</arm_group_label>
    <other_name>Basiliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Males or females, aged 18 - 70 years

          -  Recipients of de novo cadaveric, living unrelated or living related kidney transplants

          -  Females capable of becoming pregnant must have a negative serum pregnancy test within
             7 days prior to or at screening, and are required to practice an approved method of
             birth control for the duration of the study and for a period of 6 weeks following
             discontinuation of study medication, even where there has been a history of
             infertility.

          -  Patients who are willing and able to participate in the study and from whom written
             informed consent has been obtained.

        Exclusion criteria

          -  More than one previous renal transplantation

          -  Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any
             other organ, different from kidney

          -  Patients receiving a kidney from a non-heart beating donor

          -  Donor age: &lt; 5 years or &gt; 70 years

          -  Graft loss due to immunological reasons in the first year after transplantation (in
             case of secondary transplantation)

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover Muenden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <results_first_submitted>June 3, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>mycophenolate</keyword>
  <keyword>CNI-free</keyword>
  <keyword>kidney transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>.817 patients were screened and 802 were enrolled on Day of transplant which served as Baseline Visit 1. For three months post transplantation, in the pre-phase period, all patients received induction therapy (Simulect®) and immunosuppressive therapy consisting of Myfortic, Sandimmun Optoral and corticosteroids.</recruitment_details>
      <pre_assignment_details>At month 3 post transplant, Baseline Visit 2, additional eligibility was assessed and patients randomized to one of 3 treatment arms and stratified according to kidney donor (living or cadaveric).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Regimen</title>
          <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
        </group>
        <group group_id="P2">
          <title>CNI Free Regimen</title>
          <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
        </group>
        <group group_id="P3">
          <title>CNI Low Regimen</title>
          <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="802">All enrolled patients received standard regimen for 3 months</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>abnormal test procedure results</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>abnormal lab values</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized - 9 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized - Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension - 4 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Non-randomized (Followed)</title>
              <participants_list>
                <participants group_id="P1" count="95">Patients were not randomized but continued on standard regimen and entered follow up.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Regimen</title>
          <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
        </group>
        <group group_id="B2">
          <title>CNI Free Regimen</title>
          <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
        </group>
        <group group_id="B3">
          <title>CNI Low Regimen</title>
          <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="161"/>
            <count group_id="B4" value="497"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="11.8"/>
                    <measurement group_id="B2" value="48.9" spread="12.5"/>
                    <measurement group_id="B3" value="48.6" spread="12.3"/>
                    <measurement group_id="B4" value="49.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen</title>
        <description>Demonstrate superiority of CNI-Free vs Standard Regimen in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. P-values are not adjusted</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen</title>
          <description>Demonstrate superiority of CNI-Free vs Standard Regimen in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. P-values are not adjusted</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.03" lower_limit="60.57" upper_limit="65.49"/>
                    <measurement group_id="O2" value="68.59" lower_limit="66.10" upper_limit="71.08"/>
                    <measurement group_id="O3" value="63.08" lower_limit="60.62" upper_limit="65.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.82</ci_lower_limit>
            <ci_upper_limit>8.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR Via Nankivell Formula at Month 12 - All Regimens</title>
        <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR Via Nankivell Formula at Month 12 - All Regimens</title>
          <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.03" lower_limit="60.57" upper_limit="65.49"/>
                    <measurement group_id="O2" value="68.59" lower_limit="66.10" upper_limit="71.08"/>
                    <measurement group_id="O3" value="63.08" lower_limit="60.62" upper_limit="65.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR at Month 12 Utilizing Modification of Diet in Renal Disease (MDRD) Method</title>
        <description>Change in GFR (Modification of Diet in Renal Disease calculated using the –MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR at Month 12 Utilizing Modification of Diet in Renal Disease (MDRD) Method</title>
          <description>Change in GFR (Modification of Diet in Renal Disease calculated using the –MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.23" lower_limit="47.66" upper_limit="52.80"/>
                    <measurement group_id="O2" value="56.36" lower_limit="53.77" upper_limit="58.94"/>
                    <measurement group_id="O3" value="50.24" lower_limit="47.70" upper_limit="52.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR at Month 12 Utilizing Cockcroft-Gault Formula</title>
        <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR at Month 12 Utilizing Cockcroft-Gault Formula</title>
          <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.18" lower_limit="57.33" upper_limit="63.03"/>
                    <measurement group_id="O2" value="64.87" lower_limit="61.99" upper_limit="67.75"/>
                    <measurement group_id="O3" value="61.16" lower_limit="58.31" upper_limit="64.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Creatinine From Month 3 to Month 12</title>
        <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 12 post-transplant</time_frame>
        <population>Participants analyzed required at least one post randomization value. ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Serum Creatinine From Month 3 to Month 12</title>
          <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Participants analyzed required at least one post randomization value. ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="1.51" upper_limit="1.81"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.43" upper_limit="1.73"/>
                    <measurement group_id="O3" value="1.76" lower_limit="1.61" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Event Data From Baseline 2 (Month 3) to Month 6</title>
        <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
        <time_frame>From Baseline 2 (Month 3) to Month 6</time_frame>
        <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Event Data From Baseline 2 (Month 3) to Month 6</title>
          <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
          <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="1.51" upper_limit="1.81"/>
                    <measurement group_id="O2" value="15" lower_limit="1.43" upper_limit="1.73"/>
                    <measurement group_id="O3" value="10" lower_limit="1.61" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to lack of efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy failure composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Event Data Baseline 2 (Month 3) to Month 12</title>
        <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
        <time_frame>From Baseline 2 (Month 3) to Month 12</time_frame>
        <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Event Data Baseline 2 (Month 3) to Month 12</title>
          <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
          <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="1.51" upper_limit="1.81"/>
                    <measurement group_id="O2" value="20" lower_limit="1.43" upper_limit="1.73"/>
                    <measurement group_id="O3" value="13" lower_limit="1.61" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to lack of efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy failure composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL2 (Month 3) to Month 12 in Cardiovascular Risk (Framingham Score; 10-year Cardiovascular Risk)</title>
        <description>The Framingham Score (based on LDL cholesterol level) estimates the coronary heart disease risk (%) of developing one of the following coronary heart diseases: angina pectoris, myocardial infarction, or coronary disease death, over the course of 10 years.</description>
        <time_frame>From Baseline 2 (Month 3) to Month 12</time_frame>
        <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL2 (Month 3) to Month 12 in Cardiovascular Risk (Framingham Score; 10-year Cardiovascular Risk)</title>
          <description>The Framingham Score (based on LDL cholesterol level) estimates the coronary heart disease risk (%) of developing one of the following coronary heart diseases: angina pectoris, myocardial infarction, or coronary disease death, over the course of 10 years.</description>
          <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>Percent risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 1/Visit 1 (n=165,171,161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="8" lower_limit="1.51" upper_limit="1.81"/>
                    <measurement group_id="O2" value="10.2" spread="7.4" lower_limit="1.43" upper_limit="1.73"/>
                    <measurement group_id="O3" value="9.5" spread="6.9" lower_limit="1.61" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2/Month 3 (n=165,171,161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="7.7"/>
                    <measurement group_id="O2" value="8.8" spread="5.9"/>
                    <measurement group_id="O3" value="9.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=158,166,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="6.8"/>
                    <measurement group_id="O2" value="9.1" spread="6.4"/>
                    <measurement group_id="O3" value="8.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 2 to Month 12 (n=158,166,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.8"/>
                    <measurement group_id="O2" value="0.4" spread="5.1"/>
                    <measurement group_id="O3" value="-0.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR Calculated Via Nankivell Formula at Month 60</title>
        <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 60</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR Calculated Via Nankivell Formula at Month 60</title>
          <description>Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 – Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.24" lower_limit="57.11" upper_limit="63.38"/>
                    <measurement group_id="O2" value="66.98" lower_limit="63.78" upper_limit="70.17"/>
                    <measurement group_id="O3" value="58.74" lower_limit="55.58" upper_limit="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR at Month 60 Utilizing Cockcroft-Gault Formula</title>
        <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl) For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR at Month 60 Utilizing Cockcroft-Gault Formula</title>
          <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl) For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.92" lower_limit="52.36" upper_limit="59.48"/>
                    <measurement group_id="O2" value="61.6" lower_limit="57.99" upper_limit="65.2"/>
                    <measurement group_id="O3" value="52.91" lower_limit="49.32" upper_limit="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GFR at Month 60 Utilizing Modification of Diet in Renal Disease (MDRD) Method</title>
        <description>Change in GFR (Modification of Diet in Renal Disease calculated using the –MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
        <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>GFR at Month 60 Utilizing Modification of Diet in Renal Disease (MDRD) Method</title>
          <description>Change in GFR (Modification of Diet in Renal Disease calculated using the –MDRD formulat:
For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.</description>
          <population>Participants analyzed differs due to different input values requested by the different formulas (Nankivell, MDRD and Cockcroft-Gault). ITT Population consisted of all patients who were randomized at Month 3 who received at least one dose of randomized treatment. The ITT population might have included patients without any data after randomization</population>
          <units>ml/min/1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.56" lower_limit="44.58" upper_limit="50.54"/>
                    <measurement group_id="O2" value="53.41" lower_limit="50.4" upper_limit="56.42"/>
                    <measurement group_id="O3" value="44.79" lower_limit="41.83" upper_limit="47.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Creatinine From Month 3 to Month 60</title>
        <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>From randomization at BL2 (Month 3) to Month 60 post-transplant</time_frame>
        <population>Participants analyzed were previously enrolled in the core study and had at least one serum creatinine value in the extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Serum Creatinine From Month 3 to Month 60</title>
          <description>Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Participants analyzed were previously enrolled in the core study and had at least one serum creatinine value in the extension period.</population>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.72" upper_limit="2.15"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.47" upper_limit="1.91"/>
                    <measurement group_id="O3" value="2.01" lower_limit="1.79" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Event Data After Month 12 to Month 60</title>
        <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
        <time_frame>Events starting after Month 12</time_frame>
        <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>CNI Free Regimen</title>
            <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, everolimus 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, everolimus 3 mg and corticosteroids</description>
          </group>
          <group group_id="O3">
            <title>CNI Low Regimen</title>
            <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: everolimus 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: everolimus 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Event Data After Month 12 to Month 60</title>
          <description>Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).</description>
          <population>The Intention-to-treat (ITT) Population consisted of all patients who were randomized at BL2 (Month 3), and who received at least one dose of randomized treatment. Patients were analyzed according to their assigned treatment. The ITT population might have included patients without any data after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="1.51" upper_limit="1.81"/>
                    <measurement group_id="O2" value="13" lower_limit="1.43" upper_limit="1.73"/>
                    <measurement group_id="O3" value="12" lower_limit="1.61" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy failure (composite endpoint)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Regimen</title>
          <description>Myfortic, Sandimmun Optoral and corticosteroids</description>
        </group>
        <group group_id="E2">
          <title>CNI-free</title>
          <description>CNI free regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids</description>
        </group>
        <group group_id="E3">
          <title>CNI-low</title>
          <description>CNI low regimen: comprising the following steps for switching treatment:
Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>AGRANULOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BONE MARROW OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEPHROGENIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>POLYCYTHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OPTIC ISCHAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NONINFECTIOUS PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RECTAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>KIDNEY TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ANORECTAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BK VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS VIRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>EPSTEIN-BARR VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMONIA CYTOMEGALOVIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PSEUDOMEMBRANOUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PYONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL CYST INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SALPINGO-OOPHORITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SHUNT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>COMPLICATIONS OF TRANSPLANT SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>COMPLICATIONS OF TRANSPLANTED KIDNEY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GRAFT LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HEAT STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>KIDNEY RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL LYMPHOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SHUNT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TRANSPLANT DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TRANSPLANT FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VENA CAVA INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CARBOHYDRATE ANTIGEN 125 INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CREATININE URINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS TEST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>IMMUNOSUPPRESSANT DRUG LEVEL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL ACANTHOCYTES PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TUMOUR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>POST TRANSPLANT DISTAL LIMB SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CLEAR CELL RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GLOMERULOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>KIDNEY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEPHRECTASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>REFLUX NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL CYST RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URETHRAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URETHRAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VESICOURETERIC REFLUX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALVEOLITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PLEURAL FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>RESUSCITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>EMBOLISM ARTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LYMPHOCELE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VENOUS ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VENOUS OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

